Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider owned 224,215 shares in the company, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

Replimune Group stock traded up $1.59 during mid-day trading on Wednesday, reaching $15.24. The company’s stock had a trading volume of 8,269,132 shares, compared to its average volume of 5,046,735. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $15.68. The business has a 50 day moving average price of $10.34 and a 200-day moving average price of $7.64. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -4.51 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Sell-side analysts predict that Replimune Group, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Replimune Group

Hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC bought a new position in Replimune Group in the 4th quarter worth about $29,000. Russell Investments Group Ltd. boosted its position in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. CWM LLC grew its holdings in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares in the last quarter. Essential Partners LLC grew its holdings in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
• Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
• Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice

Analyst Upgrades and Downgrades

REPL has been the topic of a number of recent research reports. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, August 7th. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. JPMorgan Chase & Co. raised their price target on Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $11.86.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.